Nova Eye Secures EU MDR Certification Protecting $4.7M European Revenue Stream
Nova Eye secures critical EU certification for iTrack glaucoma devices
Nova Eye Medical (ASX: EYE) has achieved Nova Eye EU MDR Certification for its iTrack™ product portfolio, securing market access across the European Economic Area. The certification, granted by Intertek Medical Notified Body AB, enables CE marking under the EU Medical Device Regulation (EU MDR 2017/745) and replaces the company’s former certification under the now-superseded EU Medical Devices Directive.
The certification directly supports the company’s European commercial operations, which generated US$3.1 million (A$4.7 million) in sales during the 12 months ended 31 December 2025. This represents 15% of total company revenue of US$21 million (A$32 million), with European sales growing at approximately 12% year-on-year.
Nova Eye’s achievement of EU MDR compliance demonstrates regulatory capability at the highest European standard, a milestone many smaller medical device companies struggle to meet due to the framework’s enhanced requirements.
When big ASX news breaks, our subscribers know first
What is EU MDR certification and why it matters for medical device companies
The EU MDR replaced the older Medical Devices Directive with a more rigorous regulatory framework governing medical devices across the European Economic Area. The regulation introduces enhanced requirements across multiple compliance areas: risk management, clinical evidence standards, product traceability, transparency obligations, and lifecycle oversight.
For medical device manufacturers, EU MDR represents a significantly higher compliance bar than its predecessor. The framework demands more comprehensive clinical data, stricter post-market surveillance, and enhanced quality management systems. Many smaller companies have found the transition challenging, creating a competitive advantage for those that successfully navigate the certification process.
Achieving EU MDR certification signals operational maturity and regulatory capability to healthcare systems, surgeons, and investors. It demonstrates that a company’s quality systems can meet demanding international standards, creating a defensive moat against competitors unable to satisfy the stricter compliance requirements. For Nova Eye, the certification validates the robustness of its quality and regulatory infrastructure whilst removing a key execution risk from its European growth strategy.
European revenue contribution and growth trajectory
Europe represents a meaningful and growing revenue stream for Nova Eye Medical. The region’s US$3.1 million contribution grew at approximately 12% year-on-year, demonstrating sustained commercial traction in established European markets.
This growth occurs within the context of strong overall company performance. Total revenue of US$21 million increased 24% year-on-year, with Europe contributing 15% of the consolidated total.
| Metric | Value |
|---|---|
| European Sales (12 months to Dec 2025) | US$3.1m (A$4.7m) |
| European Growth (y.o.y.) | ~12% |
| Total Company Revenue | US$21m (A$32m) |
| Total Company Growth (y.o.y.) | 24% |
| Europe % of Total Revenue | 15% |
The European revenue contribution provides geographic diversification whilst the certification secures this income stream by eliminating regulatory uncertainty. Double-digit growth rates in the region indicate continued commercial momentum, supported by the company’s ability to maintain uninterrupted product supply under the new regulatory framework.
The iTrack product portfolio
Nova Eye’s iTrack™ Advance is a minimally invasive surgical device designed for treating mild-to-moderate glaucoma. The device works by restoring the eye’s natural outflow pathway, lowering intraocular pressure (the fluid pressure inside the eye) without relying on more invasive surgical approaches. For patients, this can reduce or eliminate dependence on anti-glaucoma medications.
The company’s Molteno3® drainage device targets severe glaucoma cases requiring long-term pressure control. This platform is designed for enhanced surgical utility and optimised clinical outcomes in more advanced disease presentations. It also offers the benefit of a simplified and faster surgical procedure.
Key product benefits include:
- Minimally invasive procedure approach
- Targets natural outflow restoration rather than artificial drainage
- Reduces medication dependency for glaucoma management
- Simplified and faster surgical procedure (Molteno3)
Both products are now certified for continued commercial supply across all European Economic Area countries under the EU MDR framework.
The next major ASX story will hit our subscribers first
Strategic implications for global expansion
The Nova Eye EU MDR Certification strengthens the company’s regulatory standing beyond Europe itself. Achieving certification under one of the world’s most demanding regulatory frameworks provides transferable credibility when seeking product registrations in other jurisdictions. Regulatory authorities in markets outside Europe often assess a manufacturer’s compliance history in major markets when evaluating new applications.
Nova Eye operates a global infrastructure with sales headquarters in Fremont, California, and manufacturing facilities in both Fremont and Dunedin, New Zealand. The company distributes its products through a network of international partners, supported by direct regulatory approvals in key markets.
Strategic benefits of the certification include:
- Securing existing European market access without commercial interruption
- Strengthening regulatory standing for future product registrations in new markets
- Supporting commercial expansion initiatives across multiple geographies
- Demonstrating quality systems capable of meeting the most stringent global standards
The certification removes regulatory risk from the company’s European operations whilst positioning Nova Eye to advance its commercial initiatives globally. For investors, this represents both defensive value (protecting an existing revenue stream) and offensive potential (enabling future expansion supported by enhanced regulatory credentials).
Company snapshot
Nova Eye Medical (ASX: EYE) is a medical technology company focused on developing, manufacturing, and selling ophthalmic treatment technologies and devices. The company’s products are used by eye surgeons globally.
Operational footprint includes sales headquarters in Fremont, California, with manufacturing facilities in Fremont and Dunedin, New Zealand. The company supports its global distribution through a network of international partners across multiple markets.
Want the Next MedTech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements the moment they drop, with the analysis already done for you.